Search results for: Innovation Policy Prize
Filter search results
OHE’s 50th Celebration: Publications on Tuberculosis Show Constancy and Change
23 August 2012
…40% from 1990 to 2010.[3] For TB and other deadly infectious diseases, encouraging treatment innovation is critical. Recent OHE research has focused on this important policy issue. [1] Health Protection…
Tracking Changes in the Causes of Death in England and Wales
25 October 2012
…increase in incidence rates for that disease. Innovation in health care has been important; for example, the first beta blocker was marketed in the UK in 1965, offering the first…
Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
18 February 2014
…assessments and ensure subsequent use in the marketplace. His topics included issues of evidence generation, incentives for innovation, the need for flexible approaches to ensuring patients’ access coincident with evidence…
OHE at ISPOR Europe: Posters
13 November 2014
The OHE presented the following posters at ISPOR 17th Annual European Congress in Amsterdam, The Netherlands. Ispor measuring access_pon_nd from Office of Health Economics Phill O’Neill and Nancy Devlin …
New Publication: Headroom Approach to Device Development
23 February 2016
…2014. Are the UK systems of innovation and evaluation of medical devices compatible? The role of NICE’s medical technologies evaluation programme (MTEP). Applied Health Economics and Health Policy, 12(4), pp.347-357….
Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB
24 March 2022
…to shape the innovation agenda, adding an HTA value-based purchase commitment (building on earlier advance market and purchase commitments) to “push” based development funded in product development partnerships. Whilst the…
The Expanding Value Footprint of Oncology Treatments
1 May 2014
…and reimbursement decisions that fail to adequately reward important innovation and so discourage future innovation, to the detriment of society. Public policy options for addressing this challenge include, for example,…
Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
1 February 2011
…into less investment in R&D. Differential pricing assumes that countries with lower incomes should pay lower prices, encourages the earliest possible marketing in all countries, and provides incentives for innovation….
Pharmaceutical Industry and Society: a Study of the Changing Environment and Economics of the International Industry
1 July 1972
…and that is, what is the connection between money spent on research and development and subsequent innovation? My own judgement, after listening to these lectures and reading around the subject,…